Back to Search
JUSTIN MAROUN, M.D., PH.D.
M.D., PH.D.
Surgery Physician
NPI: 1578294476IndividualAccepts Medicare
Specialties, Licenses & Credentials
Surgery PhysicianPrimary
Surgery
Code: 208600000X
74675(MN)32502(MN)
CMS Specialties
PrimaryGENERAL SURGERY
Education
MAYO MEDICAL SCHOOL
Class of 2022
Research & Publications (20)
Economic evaluation of sorafenib in the treatment of hepatocellular carcinoma in Canada.
PMID 19032137·Curr Med Res Opin·2008
3-trial
Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patients.
PMID 17194911·J Clin Oncol·2007
3-trial
Expression of thymidylate synthase in human cells is an early G(1) event regulated by CDK4 and p16INK4A but not E2F.
PMID 17923872·Br J Cancer·2007
8-other
Prevention and management of chemotherapy-induced diarrhea in patients with colorectal cancer: a consensus statement by the Canadian Working Group on Chemotherapy-Induced Diarrhea.
PMID 17576459·Curr Oncol·2007
8-other
A National Cancer Institute of Canada Clinical Trials Group Study--IND.135: Phase I/II study of irinotecan (camptosar), oxaliplatin and raltitrexed (tomudex) (COT) in patients with advanced colorectal cancer.
PMID 16330204·Eur J Cancer·2006
3-trial
Guidelines for the diagnosis and management of carcinoid tumours. Part 1: the gastrointestinal tract. A statement from a Canadian National Carcinoid Expert Group.
PMID 17576444·Curr Oncol·2006
8-other
Phase I study of Aplidine in a dailyx5 one-hour infusion every 3 weeks in patients with solid tumors refractory to standard therapy. A National Cancer Institute of Canada Clinical Trials Group study: NCIC CTG IND 115.
PMID 16966366·Ann Oncol·2006
3-trial
A phase I, first in man study of OSI-7836 in patients with advanced refractory solid tumors: IND.147, a study of the Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials Group.
PMID 16528532·Cancer Chemother Pharmacol·2006
3-trial
Nuclear expression of thymidylate synthase in colorectal cancer cell lines and clinical samples.
PMID 15956025·J Histochem Cytochem·2006
8-other
Estimating the cost of illness in colorectal cancer patients who were hospitalized for severe chemotherapy-induced diarrhea.
PMID 15729427·Can J Gastroenterol·2005
4-observational
Severe chemotherapy-induced diarrhea in patients with colorectal cancer: a cost of illness analysis.
PMID 15614493·Support Care Cancer·2005
8-other
Capecitabine as adjuvant treatment for stage III colon cancer.
PMID 15987918·N Engl J Med·2005
3-trial
Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials.
PMID 15026800·Br J Cancer·2004
3-trial
American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer.
PMID 15199089·J Clin Oncol·2004
1-meta
Adjuvant therapy for stage II colon cancer: a systematic review from the Cancer Care Ontario Program in evidence-based care's gastrointestinal cancer disease site group.
PMID 15199087·J Clin Oncol·2004
1-meta
Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial.
PMID 14630678·Ann Oncol·2003
3-trial
Lifetime costs of colon and rectal cancer management in Canada.
PMID 14733758·Chronic Dis Can·2003
8-other
Follow-up of patients with curatively resected colorectal cancer: a practice guideline.
PMID 14529575·BMC Cancer·2003
6-review
A cost comparison of oral tegafur plus uracil/folinic acid and parenteral fluorouracil for colorectal cancer in Canada.
PMID 13129416·Pharmacoeconomics·2003
4-observational
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 200 1ST ST SW
ROCHESTER, MN 55905 - Phone
- (507) 284-2511
Quick Facts
- NPI
- 1578294476
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 2
- Locations
- 1
- Years in Practice
- 4
- Publications
- 20
Are you this provider?
Claim Your Profile